Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

GLP-Compliant Droplet Digital PCR for Vector Titer Determination

PROVEN INTELLIGENCE IN VECTOR ANALYTICS.

GLP-Compliant Droplet Digital PCR (ddPCR) for Vector Copy Number Determination in ATMPs

CELL & GENE | RNA | BIOLOGICS

GLP-Compliant ddPCR for ATMP Vector Titer Determination

Executive Summary: For advanced therapy medicinal product (ATMP) developers targeting UK and EU regulatory pathways, establishing an accurate vector concentration (titer) is a foundational component of the Investigational Medicinal Product Dossier (IMPD). Droplet digital PCR (ddPCR) provides absolute quantification of vector copy number, removing the variability and inhibitor susceptibility associated with legacy qPCR methods. This analytical precision directly supports reproducible dosing in preclinical models and de-risks the CMC data package for MHRA review.

A senior scientist leads a discussion with a group of diverse junior scientists in a bright, modern laboratory setting.

Frequently Asked Questions

Why is absolute quantification of vector copy number with ddPCR important for MHRA submissions?

The MHRA requires a robust, reproducible method for determining the concentration of an ATMP. ddPCR provides absolute quantification without reliance on a standard curve, generating highly precise titer values. This data is fundamental for dose determination in IND-enabling toxicology studies and for establishing consistent product specifications in the CMC section of an IMPD or IND.

How does ddPCR improve upon qPCR for determining AAV vector copy number in GxP environments?

Unlike qPCR, which provides relative quantification, ddPCR partitions a sample into thousands of droplets, allowing for a direct count of target DNA molecules. This method demonstrates superior precision and is less susceptible to PCR inhibitors often present in complex biological samples. For AAV vector copy number analysis under GxP conditions, this translates to lower inter-assay variability and a more reliable data package for regulatory review.

What is the role of ddPCR in supporting non-target tissue biodistribution studies?

Accurate biodistribution analysis depends on the ability to detect and quantify very low levels of vector DNA in various tissues. The high sensitivity and precision of ddPCR make it the definitive method for these studies. It provides reliable data on vector localization and clearance, which is a key safety component required by regulatory bodies.

For next-generation therapies, particularly AAV-based constructs, the accuracy of vector titer determination directly impacts every subsequent phase of development. Inconsistent quantification introduces variability into preclinical dosing, complicates the interpretation of toxicology and biodistribution data, and undermines the integrity of a regulatory submission.

A close-up shot of a scientist in a lab coat and blue gloves using a micropipette to transfer a liquid sample into a small test tube.

The Shift to Absolute Quantification

The analytical standard for vector titering has moved towards methods that provide absolute, rather than relative, data. Droplet digital PCR meets this requirement by partitioning the sample into thousands of discrete reactions, enabling a direct digital count of target molecules.

This approach offers distinct advantages for programs preparing for regulatory interactions:

  • Elimination of Standard Curves: ddPCR does not require a reference standard curve for quantification, removing a significant source of potential assay variability.

  • Enhanced Precision: The method delivers higher precision and reproducibility compared to qPCR, which is vital for establishing lot-to-lot consistency for an ATMP.

  • Inhibitor Resistance: Its tolerance to common PCR inhibitors found in processed samples ensures more reliable results from complex matrices.

The robustness of ddPCR for quantifying AAV vector DNA has been validated as a superior analytical tool for CMC applications (PMID: 24328707). This level of analytical certainty is foundational for building a data package that can withstand regulatory scrutiny.

From Analytics to In Vivo Performance

The precision of vector characterization is a foundational CMC activity that directly links to predictable therapeutic outcomes. Establishing an accurate vector titer ensures that dosing in pivotal IND-enabling toxicology studies is correct and reproducible. This precision was instrumental in a study where an optimized AAV vector, when properly characterized and dosed, corrected neurological disease in a preclinical model (PMID: 33045869). This demonstrates that reliable analytics are a prerequisite for achieving the desired biological effect and generating a clear, interpretable safety profile.

Our analytics are performed within our GxP-compliant, >100,000 sq ft facilities, ensuring that the data generated meets the stringent requirements for MHRA and FDA submissions. As one biotech partner noted, our team has a “Vast knowledge in all aspects of vector production and analytics.” This expertise is applied to every program, ensuring the analytical strategy aligns with the overall clinical and regulatory goals.

This analytical rigor is a core component of our work supporting sponsors through the entire preclinical pathway. For more information on our broader capabilities, please see our primary Vector | CMC | Analytics Services page.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities